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Exosomes, small lipid bilayer vesicles, are part of the transportable cell secretome that
can be taken up by nearby recipient cells or can travel through the bloodstream to
cells in distant organs. Selected cellular cytoplasm containing proteins, RNAs, and other
macromolecules is packaged into secreted exosomes. This cargo has the potential to
affect cellular function in either healthy or pathological ways. Exosomal content has
been increasingly shown to assist in promoting pathways of neurodegeneration such as
β-amyloid peptide (Aβ) accumulation forming amyloid plaques in the brains of patients
with Alzheimer’s disease, and pathological aggregates of proteins containing α-synuclein
in Parkinson’s disease transferred to the central nervous system via exosomes. In
attempting to address such debilitating neuropathologies, one promising utility of
exosomes lies in the development of methodology to use exosomes as natural delivery
vehicles for therapeutics. Because exosomes are capable of penetrating the blood-brain
barrier, they can be strategically engineered to carry drugs or other treatments, and
possess a suitable half-life and stability for this purpose. Overall, analyses of the roles that
exosomes play between diverse cellular sites will refine our understanding of how cells
communicate. This mini-review introduces the origin and biogenesis of exosomes, their
roles in neurodegenerative processes in the central nervous system, and their potential
utility to deliver therapeutic drugs to cellular sites.
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EXOSOME BIOGENESIS
Exosomes were first reported (Pan and Johnstone, 1983) as a way red blood cells (RBCs) released
excess cell membrane. It has since been realized that exosomes, defined as extracellular vesicles
approximately 30–120 nm diameter size, are another member of the cellular secretome, acting as
both a paracrine messenger affecting adjacent cells and a systemic messenger circulating in the
blood. Exosomes develop from the in-budding of endosomes, which in turn forms multi-vesicular
bodies (MVBs) that contain intra-luminal vesicles (ILVs) (Cocucci andMeldolesi, 2015). TheMVBs
then fuse with the cell membrane of various cell types to release ILVs extracellularly as exosomes,
which then serve as messengers communicating with other cells. Through such intercellular
communication—including penetration of the blood brain barrier—exosomes represent optimal
targets to harness as a drug delivery vehicle of therapeutic cargo (Stremersch et al., 2016).
Exosomes carry intracellularly sorted cargo that is encapsulated in a lipid bilayer bound vesicle.
The MVBs carry ILVs to the cytoplasmic side of the plasma membrane where the MVB fuses
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and releases the ILVs as exosomes to the extracellular space
near recipient cells. Alternatively, the endosome can fuse with
a lysosome where the contents of the MVB are degraded
and recycled within the cell (Figure 1). The exosome’s internal
cargo reflects the status of the cell’s health and/or disease and
may affect nearby cells by binding to their membranes and
extruding their cargo (Eitan et al., 2016). A growing body of
evidence suggests that exosomes can influence both cell health
and pathology of cells by the content of the vesicle (Pegtel
et al., 2014). Investigators are also exploring the use of these
nanoparticles as natural therapeutic delivery vehicles. They can
travel systemically, can pass through the blood-brain barrier (Li
et al., 2017), can escape stimulating immune responses, and,
because the lipid vesicle protects the exosomal contents, can resist
degradation from both endogenous and exogenous enzymes and
RNAses.
EXOSOME CONTENT
The biological content of exosomes (Figure 2) consists of lipids,
proteins and RNAs that can be transferred to recipient cells
where they can trigger cellular responses (Lopez-Verrilli et al.,
2016; Willms et al., 2016). Exosome content is determined at
the budding endosome compartment and requires active sorting
by specific proteins of the endosomal sorting complex (ESCRT)
to package the cargo. Two proteins from this complex ALIX
(ALG2 interacting protein X) and TSG101 (tumor susceptibility
gene 101) are commonly found in exosomes and used as marker
proteins. Flottilin-1 is also found in exosomes as a marker
protein. There also appears to be an ESCRT independent path
to exosome cargo sorting (Trajkovic et al., 2008; Villarroya-
Beltri et al., 2014; Zhang et al., 2015). A complete database of
exosomal proteins can be found at Exocarta (www.exocarta.org)
(Keerthikumar et al., 2015) where over 100 proteins are listed
as exosomal biomarkers. Exosomes are likely aheterogeneous
population of vesicles in which cargo can differ depending on
the physiological state of the cell producing the exosomes and
the sorting mechanisms invoked for packaging. For example,
exosome analysis of vesicle release from cancer cells (Palma et al.,
2012) suggested that there were customized particles containing
specific miRNAs. Thus, each cell releasing exosomes may be
customizing subpopulations of vesicles containing differentially
defined cargo (Willms et al., 2016). Exosome content also varies
with the cell source of the exosomes. RNA populations in
exosomes appear distinct from the cytoplasmic RNA profile
suggesting active sorting to the exosomes (Baglio et al., 2015). It
is reported that exosomes have specific miRNA profiles, perhaps
indicating putative targets of regulation in the recipient cell.
Baglio et al. (2015), reported that five miRNAs accounted for 50%
of the exosomal content of bone marrow derived mesenchymal
stem cells (BMSC) and that these miRNAs function in bone
marrow differentiation and proliferation. In addition to miRNA
content, there is a substantial collection of tRNA and tRNA halves
that may also contribute to cellular regulation in some way.
Many investigators have focused on the selective cargo found
in exosomes and these continued explorations will inform our
understanding of exosome function in the future.
EXOSOMES AS POTENTIAL THERAPY
TOOLS
The ability of exosomes to communicate among cells locally
and systemically has prompted evaluation of repurposing these
vesicles as carriers of therapy (Figure 3) for a number of
diseases such as cardiomyopathies (Loyer et al., 2014; Iaconetti
et al., 2016; Ibrahim and Marban, 2016), cancer (Ahadi
et al., 2016; Aqil et al., 2016; Choy and Jandial, 2016), and
neurodegeneration diseases (Kalani et al., 2014; Bellingham et al.,
2015; Kramer-Albers and Hill, 2016). Exosomes from cellular
sources (bone marrow, mesenchymal stem cells, and others)
or re-engineered exosomes that carry selected cargo (drugs,
therapeutic proteins, and others) are able to transport cargo
across the blood-brain barrier and deliver it to the brain (Andras
and Toborek, 2016). It follows that if the cargo storage and
system transport capacity of exosomes can be adapted to carry
therapeutic entities to diseased brain regions, exosomes may
be used to help alleviate a wide range of neuropathologies.
Exosome secretion has been confirmed from different cell
sources including neurons (Janas et al., 2016), microglia (Brites
and Fernandes, 2015), astrocytes (Verkhratsky et al., 2016),
oligodendrocytes (Budnik et al., 2016), and neural stem cells
(Sims et al., 2014), and their presence in cerebrospinal fluid has
also been reported (Chiasserini et al., 2014). Recent findings
suggest that exosomes contain unique biological cargo that
represent the physiological health or pathophysiological state
of their originating cell source (Kalani et al., 2014). Exosomes
have several features that make them accessible as a novel
therapeutic strategy for neurological diseases. They are cellular
derived membrane bound vesicles that function as biological
transporters; they carry unique, sequestered cargoes between
adjacent cells and organs; and they can efficiently cross the
blood-brain barrier. Caponnetto et al. (2016) and others have
shown that exosomes labeled with DiD from a patient’s glioma
are efficiently taken up by A172 cultured cells. However,
they also show that the isolation method (ultracentrifugation
or ExoQuick) yields significant exosome size differences that
potentially may affect physical uptake or biological function.
Another confounding parameter for evaluation of exosomes
as an effective nanotherapeutic is the mechanism of exosome
uptake into target cells. It is suggested that exosomes enter
cells in multiple ways (endocytosis, plasma membrane fusion,
macropinocytosis, and others) so each entry method should
be evaluated for efficacious delivery and exosomes potentially
designed with “zip codes” to utilize the best delivery route. Since
exosomes can deliver cargo directly to recipient cells, the capacity
to deliver large amounts of cargo to target cells might be leveraged
to include therapeutics in engineered exosomes (Armstrong et al.,
2017). This cannot efficiently be achieved with soluble factors
only.
Exosomes administered in vivo are shown to reduce
apoptosis, alter inflammation, reduce cancer growth and enhance
myocardial viability (Armstrong et al., 2017). Other small
synthetic vectors (liposomes) have been considered for therapy
approaches. However, the bioavailability and innate biological
nature of exosomes makes them very promising vehicles for
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FIGURE 1 | Exosome Biogenesis. Cytoplasmic cargo is selected by sorting mechanisms (as yet not comprehensively elucidated) and placed into early endosomes.
The endosomes may then enter the lysosomal degradation pathway where the exosome contents are degraded and recycled for cellular use or removed as debris. In
the second pathway, the endosome forms a multivesicular body (MVB) containing many intraluminal vesicles (ILVs). The MVB can deliver the ILV to the plasma
membrane where they are extruded and become exosomes. These exosomes may act as cell to cell messengers to nearby recipient cells or be picked up in the
circulation from the extracellular space. Consequently, exosomes may affect distant cellular sites by being captured at their plasma membranes by receptor-ligand
interactions. See references (Keller et al., 2006; Trajkovic et al., 2008; Colombo et al., 2014; Kowal et al., 2014; Hurley, 2015) for further detail.
FIGURE 2 | Exosome Content. Exosomes are a bilayer lipid membrane that encapsulate cellular cargo selected from the cytoplasm by sorting mechanisms. The
lipid membrane may also contain ligands for recipient cell receptors at near or distant systemic sites. Cataloged in exocarta.org is a list of commonly found proteins
and RNAs in exosomes. Recent analyses of exosomes from neurodegenerative cells have documented disease-associated cargoes in the exosomes. For further
details see references (Bellingham et al., 2012a,b; Taylor and Shah, 2015; Benussi et al., 2016; Willms et al., 2016).
therapy. For example, catalase is a promising treatment for
Parkinson’s Disease but the inability to transport it across the
blood-brain barrier in drug loaded nanoparticles encountered
two problems, nanotoxicity of the formulation and activation and
rapid clearance of the particles by phagocytosis (Haney et al.,
2015). A formulation of catalase (exoCAT) obtained by drug-
loading exosomes reached target neurons and accumulated in
these cells in a Parkinson’s mouse model (Haney et al., 2015).
Much work needs to be done to assess parameters that need to be
met for re-engineering exosomes to a therapeutic role but many
promising studies are ongoing (see review by Armstrong et al.,
2017).
Exosome therapy also offers safety and regulatory advantages
(Lamichhane et al., 2015a) over therapeutic ex-vivo cell
replacement infusions. First, exosomes do not endogenously
replicate, as cells would, and thus cannot become metastatic.
Second, exosomes are bilipid vesicles that can contain a
manufactured cargo and, consequently, can be bioengineered for
quality control and scaled up for dose. Therapeutic exosomes
might also be derived from the patient’s own cells to reduce or
eliminate potential immunological complications. In addition to
isolating exosomes from the patient’s own cells, plant cell sources
(Ju et al., 2013) for cargo engineered exosomes has not escaped
consideration (Xitong and Xiaorong, 2016).
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FIGURE 3 | Exosomes as carriers of therapeutics. It is proposed that natural or synthetic exosomes could be used as therapeutic tools because the lipid-bound
vesicles resist degradation. They are shown to carry and deliver cargo via a secretome from one cell to another. Exosomes have the unusual ability to cross the
blood-brain barrier and therefore present a unique opportunity to deliver therapeutics to targeted brain regions. See references (Lamichhane et al., 2015b; Lener et al.,
2015; Aryani and Denecke, 2016; Lopez-Verrilli et al., 2016; Yim and Choi, 2016) for further detail.
Yet with all of the apparent advantages that exosome therapy
might offer, there remain barriers to be solved before these
therapeutic strategies can be widely implemented. The exosome’s
loading capacity and the half-life of the cargo need to be
determined to understand engineered synthetic cargoes for
therapeutics. There needs to be a pharmacological consideration
of exosome dosage and assessments of their biodistribution
when administered systemically. Finally, the kinetics of exosome
uptake at the target cell must be determined, as well as whether
the therapeutic delivery of exosome cargo requires bioengineered
ligands on the vesicle surface to increase delivery success to
selected targets. Further development of exosome therapeutic
strategies will require continued investigations into exosome
biology.
EXOSOMES: TARGETED THERAPEUTIC
APPROACHES TOWARD
NEURODEGENERATION
Cerebral-derived exosomes are demonstrated to carry unique
cargoes and to facilitate cross-talk between and among
brain regions in coordination with complex brain activities.
The exosome’s cargo can mediate neuronal protection and
development, nerve regeneration and synaptic plasticity (Lopez-
Leal and Court, 2016; Lopez-Verrilli et al., 2016; Wei et al., 2016).
Also, it is reported that exosomes deliver regulatory elements to
neurological injury sites that appear to aid in protein synthesis
and tissue regeneration (De Rivero Vaccari et al., 2016; Wei
et al., 2016). Conversely, in other instances, they have a role in
fostering neurological disease progression. In addressing issues of
neurodegeneration, exosomes have been utilized with particular
success against such pathologies as stroke, Amyotrophic Lateral
Sclerosis (ALS), Alzheimer’s disease, dementia, and Parkinson’s
disease, as detailed below.
Mesenchymal stem cell-derived exosomes are shown to
yield tissue-protective effects in stroke models following neural
injury resulting from middle cerebral artery occlusion (Xin
et al., 2012). Neurite branch number and length was shown to
increase significantly following delivery of mesenchymal stem
cell-derived exosomes (Yu et al., 2011). This success presumably
resulted from exosomal transfer of microRNA 133 b that has
been shown to facilitate neuronal recovery following spinal cord
injury (Yu et al., 2011).
Exosomes circulating in the blood also appear to have
significant effects on immune responses, which in turn carry
implications for neurodegenerative and neuroinflammatory
disease states. In particular, ALS (also known as Lou Gehrig’s
disease) is a fatal, progressive, adult-onset neurodegenerative
disease that preferentially impacts upper and lower motor
neurons in the cerebral cortex and spinal cord, respectively.
This neurodegeneration is accompanied by neuroinflammatory
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reactions including activation of microglia in the central
nervous system (Turner et al., 2004; Boillee et al., 2006)
and additional involvement of the peripheral immune system
(Kuhle et al., 2009; Zondler et al., 2016b). Recent studies have
demonstrated impaired pro-inflammatory cytokine secretion
following exosomal stimulation in peripheral monocytes from
ALS donors (Zondler et al., 2016a). In addition, exosomal
TDP-43 (transactive response DNA-binding protein 43 kD; an
aggregation-prone protein characteristic in the histopathology
of ALS) was shown to increase monocyte activation (Zondler
et al., 2016a). Peripheral monocytes are capable of entering the
central nervous system in the ALS disease state (Zondler et al.,
2016b). Because monocytes demonstrated preferential uptake of
exosomal (compared to free) TDP-43 (Zondler et al., 2016a), the
collective evidence indicates that exosomes may serve as immune
messengers mediating TDP-43 infiltration of the central nervous
system. This in turn may contribute toward (and indicate a target
for addressing) the pathogenesis of ALS, including increased
neuroinflammation and neurodegeneration.
In addition to immune effects, mutations in the Fused
in Sarcoma/Translocated in Liposarcoma (FUS/TLS) gene are
thought to contribute to ALS pathogenesis. FUS/TLS interacting
partners were identified as exosomal components, and FUS/TLS
itself was localized to exosomes (Kamelgarn et al., 2016).
FUS/TLS secretion from exosomes may contribute to the
communication and spread of this mutation. Thus, exosomes
represent a viable target in alleviating the disease progression,
pathology, and symptomology characterizing ALS.
Recent studies have also demonstrated that exosomes
represent viable therapeutic targets against Alzheimer’s disease.
Alzheimer’s disease is characterized by progressive neuronal
loss, neurofibrillary tangles, and an overabundance (and lack of
degradation) of β-amyloid peptide (Aβ) in the brain forming
amyloid plaques (Hickman et al., 2016). In an attempt to
address this imbalance of Aβ accumulation, adipose tissue-
derived mesenchymal stem cells have been used to secrete
exosomes containing neprilysin (Katsuda et al., 2013). This
enzyme is capable of degrading Aβ, thereby offering a potential
therapeutic tool via exosomal delivery of neprilysin. This
in turn might alleviate Aβ accumulation, and ultimately
Alzheimer’s symptomology. Mouse models also have been
utilized in exosome-centered therapies targeting Alzheimer’s
disease. Electroporation was used to equip dendritic cell-derived
exosomes with short interfering RNA (siRNA) for delivery to
the brain, crossing the blood- brain barrier (Alvarez-Erviti et al.,
2011). Exosome delivery of siRNA resulted in a significant and
dose- dependent knockdown of the mRNA and protein for
BACE1, a protease that produces N-terminal cleavage of amyloid
precursor proteins that lead to Aβ aggregations. Thus, targeted
exosomal delivery of siRNA has the potential to cross the blood-
brain barrier to reach the brain and generate specific knockdown
to alleviate the pathogenesis of Alzheimer’s disease.
Frontotemporal dementia (also known as frontotemporal
lobar degeneration, or FTLD) is, as the name suggests, a group
of disorders that are characterized by atrophy of the frontal
and temporal lobes of the brain. FTLD tends to occur in a
younger age group than that associated with Alzheimer’s disease,
typically between the ages of 40–65. Mutations in the progranulin
gene (GRN), leading to a loss of functional progranulin proteins
associated with exosomes, are a leading cause of FTLD (Baker
et al., 2006; Cruts et al., 2006). Null mutations in GRN are
shown to significantly reduce the quantity of exosomes released,
and the resulting reduction of progranulin in the brain is
thought to underlie the neurodegeneration characterizing FTLD
cases associated with GRN mutations (Benussi et al., 2016).
This GRN-associated alteration of cell-to-cell communication
through exosomes offers a therapeutic target in addressing one
aspect of the multifaceted underlying causes of dementia.
Parkinson’s disease represents an additional pathological
target that is amenable to exosome- centered therapeutic
approaches. Parkinson’s disease is characterized by a variety
of pathological hallmarks, including microglia-mediated
neuroinflammation, loss of dopaminergic neurons in the
substantia nigra of the midbrain and accumulation of Lewy
bodies (aggregates of proteins containing α-synuclein).
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene have
been linked to inherited Parkinson’s disease (Paisan-Ruiz et al.,
2004; Zimprich et al., 2004; Gilks et al., 2005; Khan et al., 2005;
Nalls et al., 2014). A recent study demonstrated that levels of
autophosphorylated Ser(P)-1292 LRRK2 are elevated in urinary
exosomes in cases of idiopathic Parkinson’s disease (Fraser
et al., 2016). This study further correlated cognitive impairment
severity and difficulty in performing daily activities with levels
of urinary exosome Ser(P)-1292 LRRK2 (Fraser et al., 2016),
indicating exosomal delivery of genetic mutations linked to
Parkinson’s disease and offering a potential therapeutic target
with high specificity. The ability to capture the Ser(P)-1292
LRRK2 containing exosomes in the urine also offers an accessible
biomarker of this form of Parkinson’s disease.
Misfolded proteins have been implicated in a range of
neurodegenerative pathologies, using exosomes to spread the
misfolded proteins characteristic of each disease and the end
result is to worsen pathogenesis. Such misfolded proteins and
their associated neuropathologies include: superoxide dismutase
1 protein in ALS, β-amyloid and tau proteins in Alzheimer’s
disease, and α-synuclein protein in Parkinson’s disease (Wu et al.,
2016; Quek and Hill, 2017). Exosomes are not only capable of
transmitting misfolded proteins associated with disease states,
but also of facilitating pathological aggregations of proteins
(and subsequent transmission of these aggregates to previously
aggregate-free areas of the central nervous system), thereby
expediting neurodegeneration (Howitt and Hill, 2016).
CONCLUSIONS
It is now understood that exosomes play a key role in brain
health and disease. Over the last several years, investigators have
come to appreciate the biogenesis of exosomes, their role as
cell- cell transporters and communicators and their function
as part of the cell’s secretome. These exosomal activities are
appreciated to extend the cell’s capacity to deliver both beneficial
and detrimental molecules across the systemic organism. Due
to the exosomes ability to carry diverse cargoes, they are
now considered to be ideal vehicles for delivery of therapeutic
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molecules to previously inaccessible regions of the brain.
Continued exosome studies and their mechanisms and utility will
optimize novel, targeted therapeutic approaches in addressing a
wide range of devastating diseases.
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